Use of an antineoepitope antibody for identification of type-II collagen degradation in equine articular cartilage

American Journal of Veterinary Research

Volumn 62, Issue 7, 2001, Pages 1031-1039

  Billinghurst, R Clark ^a   Buxton, Elizabeth M ^a   Edwards, Michael G ^a,b   McGraw, Megan S ^a   McIlwraith, C Wayne ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUIDAE; EQUUS CABALLUS; MAMMALIA;

ANTIBODY; ANTINEOPLASTIC AGENT; COLLAGEN TYPE 2; COLLAGENASE; EPITOPE; ORGANIC COMPOUND; PEPTIDE FRAGMENT; PROTEOGLYCAN; STROMELYSIN; TANOMASTAT;

ANIMAL; ANIMAL DISEASE; ARTICLE; ARTICULAR CARTILAGE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORSE; HORSE DISEASE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; OSTEOARTHRITIS; PATHOLOGY; RABBIT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; COLLAGENASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HORSE DISEASES; HORSES; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 3; ORGANIC CHEMICALS; OSTEOARTHRITIS; PEPTIDE FRAGMENTS; PROTEOGLYCANS; RABBITS;

EID: 0035405863     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2001.62.1031     Document Type: Article

References (24)

1. Billinghurst RC, Wu W, Ionescu M, et al. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum 2000; 43:664-672.
2. Jubb RW, Fell HB. The breakdown of collagen by chondrocytes. J Patlhol 1980;130:159-167.
3. Dodge GR, Poole AR. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin-1. J Clin Invest 1989;83:647-661.
4. Hollander AP, Heathfield TF, Webber C, et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994;93:1722-1732.
5. Hollander AP, Pidoux I, Reiner A, et al. Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest 1995;96:2859-2869.
6. Billinghurst RC, Dahlberg L, Ionescu M, et al. Enhanced cleavage of type II collagen in osteoarthritic cartilage. J Clin Invest 1997;90:1534-1545.
7. Dahlberg L, Billinghurst RC, Manner P, et al. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthelic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum 2000;43:673-682.
8. Liu X, Wu H, Byrne M, et al. A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling. J Cell Biol 1995;130:227-237.
9. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
10. Vankemmekbeke M, Dekeyser PM, Hollander AP, et al. Characterization of helical cleavages in type II collagen generated by matrixim. Biochem J 1998;330:633-640.
11. Otterness IG, Downs JT, Lane C, et al. Detection of collagenase-induced damage of collagen by 9A4, a monoclonal C-terminal neoepitope antibody. Matrix Biol 1999;18:331-341.
12. Billinghurst RC, O'Brien K, Poole AR, et al. Inhibition of articular cartilage degradation in culture by a novel nonpeptidic matrix metalloproteinase inhibitor. Ann N Y Acad Sci 1999;878:594-597.
13. Richardson DW, Dodge GR. Cloning of equine type II procollagen and the modulation of its expression in cultured equine articular chondrocytes. Matrix Biol 1997;16:59-64.
14. Hughes CE, Caterson B, White RJ, et al. Monoclonal antibodies recognizing protease-generated neoepitopes from cartilage proteoglycan degradation. J Biol Chem 1992;267:16011-16014.
15. Kielty CM, Hopkinson I, Grant ME. Collagen. The collagen family. In: Royce PM, Steinmann B, eds. Connective tissue and its heritable disorders. New York: Wiley-Liss, Inc, 1992;103-147.
16. Laemmli UK. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (Lond) 1970;227:680-685.
17. Smith CL, MacDonald MH, Tesch AM, et al. In vitro evaluation of the effect of dimethyl sulfoxide on equine articular cartilage matrix metabolism. Vet Surg 2000;29:347-357.
18. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986;883:173-177.
19. Goldring MB, Birkhead J, Sandell LJ, et al. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 1988;82:2026-2037.
20. Ellis AJ, Curry VA, Powell EK, et al. The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem Biophys Res Commun 1994;201:94-101.
21. Spiroto S, Doughty J, O'Byrne E, et al. Metalloproteinase inhibitors halt collagen breakdown in IL-1 induced bovine nasal cartilage cultures. Inflamm Res 1995;44(suppl 2):S131-132.
22. Chichester CO, Barrach HJ, Srinivas GR, et al. Immunological detection of type II collagen degradation: use in the evaluation of anti-arthritic therapies. J Pharm Pharmacol 1996;48:694-698.
23. Bonassar LJ, Sandy JD, Lark MW, et al. Inhibition of cartilage degradation and changes in physical properties induced by IL-1β and retinoic acid using matrix metalloproteinase inhibitors. Arch Biochem Biophys 1997;344:404-412.
24. Kozaci LD, Buttle DJ, Hollander AP. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum 1997;40:164-174.